|
|
| Research article summary (published 28 Feb 2008): |
Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?
Full Abstract
To produce its characteristic effects, a drug must be present in appropriate concentrations at its sites of action. The latter is not only a function of the dose administered, but also of the extent and rate of drug absorption, distribution, tissue binding, biotransformation, and excretion, which can vary markedly between individual patients due to differences in gender, age, morbidity, smoking or eating habits, differential expression of drug metabolising enzymes or drug transporters or other factors. Therefore drug concentrations in blood resulting after a given dose differ by tenfold or more between individual patients. For psychoactive drugs, animal studies have shown that plasma concentrations of psychotropic drugs correlate well with concentrations in the target organ, the brain. In the brain of patients treated with antipsychotic or antidepressant drugs clear-cut relationships were found between plasma concentrations of the drug and occupancy of dopamine receptors or serotonin uptake sites by positron emission tomography (PET). Monitoring concentrations of psychoactive drugs in plasma of patients, so called therapeutic drug monitoring (TDM), is therefore useful to adjust dosages for optimal "receptor" blockade. TDM is well established for mood stabilizers and anticonvulsant drugs. For other neuropsychiatric drugs, however, "routine" TDM is rare. Optimal target concentrations are unclear for many drugs, and the number of laboratories that use reliable methods to measure the low concentrations of the drugs within a single day is quite limited. Moreover, the use of TDM in practice is far from optimal. The TDM group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP see http://www.agnp.de/) has published literature-based guidelines for optimal use of TDM in psychiatry. TDM can be most informative to solve problems underlying the treatment of an individual patient. It can be clarified if suggested non-compliance or insufficient response in spite of recommended doses is due to rapid metabolism of the drug. Moreover, many drug interactions have been detected by using TDM. In conclusion, TDM is a reliable tool to optimise psychopharmacotherapy. When used adequately it is helpful for many psychiatric patients and in many situations.
Learn Faster Today Improve your study skills
Author information
Author/s: Hiemke, Christoph (C);
Affiliation: Department of Psychiatry, University of Mainz, Untere Zahlbacher Str 8, Mainz, Germany. hiemke(-atsign-)mail.uni-mainz.de
Journal and publication information
Publication Type: Journal Article; Review
Journal: European archives of psychiatry and clinical neuroscience (Eur Arch Psychiatry Clin Neurosci), published in Germany. (Language: eng)
Reference: 2008-Mar; vol 258 Suppl 1 (issue ) : pp 21-7
Dates: Created 2008/03/17; Completed 2008/05/06;
PMID: 18344046, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
These are the highest related articles currently in the database:
- Abstracts of the European College of Neuropsychopharmacology Workshop on Neuropsychopharmacology for Young Scientists in Europe. Nice, France, March 3-6, 2005.
27 Feb 2005 - Abstracts of the 18th European College of Neuropsychopharmacology Congress, Amsterdam, The Netherlands, October 22-26, 2005.
29 Sep 2005 - Abstracts of the 20th European College of Neuropsychopharmacology (ECNP) Congress, 13-17 October 2007, Vienna, Austria.
29 Sep 2007 - [Deleted Record]
28 Feb 2008 - New treatments for chronic lymphocytic leukemia.
30 Aug 2007 - Abstracts of the 8th European College of Neuropsychopharmacology (ECNP) Regional Meeting. Moscow, Russia, April 14-16, 2005.
30 Mar 2005 - MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline.
30 Dec 2005 - Dried blood spot measurement of tacrolimus is promising for patient monitoring.
25 Jan 2007 - Immunogenicity of protein therapeutics.
23 Oct 2007 - Proteomics and cardiovascular disease: an update.
30 Dec 2007
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.